WO2003087124A3 - Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales - Google Patents
Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales Download PDFInfo
- Publication number
- WO2003087124A3 WO2003087124A3 PCT/US2003/010240 US0310240W WO03087124A3 WO 2003087124 A3 WO2003087124 A3 WO 2003087124A3 US 0310240 W US0310240 W US 0310240W WO 03087124 A3 WO03087124 A3 WO 03087124A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood vessels
- tumor
- tumor cells
- melecules
- hmgn2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003228431A AU2003228431A1 (en) | 2002-04-05 | 2003-04-02 | Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11686602A | 2002-04-05 | 2002-04-05 | |
US10/116,866 | 2002-04-05 | ||
US10/400,083 | 2003-03-20 | ||
US10/400,083 US7544767B2 (en) | 2002-04-05 | 2003-03-20 | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003087124A2 WO2003087124A2 (fr) | 2003-10-23 |
WO2003087124A3 true WO2003087124A3 (fr) | 2006-08-17 |
Family
ID=29253938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/010240 WO2003087124A2 (fr) | 2002-04-05 | 2003-04-02 | Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003228431A1 (fr) |
WO (1) | WO2003087124A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
CN1862258B (zh) * | 2005-05-12 | 2012-05-30 | 清华大学 | 核仁素辅助的癌症诊断与治疗方法 |
US8231895B2 (en) | 2008-05-22 | 2012-07-31 | Universidade De Coimbra | Targeted delivery to human diseases and disorders |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
WO2011119058A2 (fr) | 2010-03-22 | 2011-09-29 | Universidade De Coimbra | Nanoparticules lipidiques vectorisées par le peptide f3, utiles pour le traitement de maladies liées à une angiogenèse |
EP2555802A1 (fr) * | 2010-04-08 | 2013-02-13 | Sanford-Burnham Medical Research Institute | Méthodes et compositions pour une administration améliorée de composés |
ES2690557T3 (es) | 2011-06-02 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Nanopartículas conjugadas a un agente antinucleolina |
WO2016127346A1 (fr) * | 2015-02-11 | 2016-08-18 | 四川大学华西医院 | Variant du ligand induisant l'apoptose associé au facteur de nécrose tumorale, son procédé de préparation et son utilisation |
WO2016172515A1 (fr) | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Système d'administration ciblée et procédés d'utilisation correspondants |
WO2016179394A1 (fr) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Nanoparticules conjuguées à un agent antinucléoline en tant que radiosensibiliseurs et agents de contraste d'imagerie par résonance magnétique (irm) et/ou en rayons x |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468758B1 (en) * | 1998-09-23 | 2002-10-22 | Corixa Corporation | Compositions and methods for ovarian cancer therapy and diagnosis |
-
2003
- 2003-04-02 WO PCT/US2003/010240 patent/WO2003087124A2/fr not_active Application Discontinuation
- 2003-04-02 AU AU2003228431A patent/AU2003228431A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468758B1 (en) * | 1998-09-23 | 2002-10-22 | Corixa Corporation | Compositions and methods for ovarian cancer therapy and diagnosis |
Non-Patent Citations (2)
Title |
---|
PORKKA ET AL: "A Fragment of the HMGN2 Protein Homes to the Nuclei of Tumor Cells and Tumor Endothelial Cells In Vivo", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 11, May 2002 (2002-05-01), pages 7444 - 7449, XP002904203 * |
WALKER R. ET AL.: "The Partial Amino Acid Sequence of a Non-Histone Chromosomal Protein", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 73, no. 1, November 1976 (1976-11-01), pages 72 - 78, XP024845966, DOI: doi:10.1016/0006-291X(76)90498-8 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003228431A8 (en) | 2003-10-27 |
AU2003228431A1 (en) | 2003-10-27 |
WO2003087124A2 (fr) | 2003-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005116051A3 (fr) | Peptides specifiques de tumeurs, se fixant sur des molecules cmh | |
CA2560278A1 (fr) | Proteines bouganine, cytotoxines et leurs procedes et utilisations | |
WO2001008636A8 (fr) | Polypeptides et polynucleotides ameliorant la reactivite immunitaire a la proteine her-2 | |
WO2005122379A3 (fr) | Ligands d'integrine alpha-4 beta-1 destines a l'imagerie et utilises en therapie | |
WO2005051998A3 (fr) | Anticorps | |
WO2006087637A3 (fr) | Anticorps | |
MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
WO2003087124A3 (fr) | Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales | |
WO2003059951A8 (fr) | Anticorps anti-igf-ir et leurs applications | |
WO2005058967A3 (fr) | Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications | |
MXPA04004417A (es) | Anticuerpo anti-tnf alfa modificado. | |
RU2009114161A (ru) | Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника | |
WO2000066175A3 (fr) | Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate | |
RS20100555A (en) | HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS | |
EP2535355A3 (fr) | Anticorps diriges contre CD38 pour le traitement du myelome multiple | |
EP2431050A8 (fr) | Procédés pour traiter le cancer au moyen d'IL-21 et une thérapie par anticorps monoclonaux | |
AU2003296330A1 (en) | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions | |
WO2007018619A3 (fr) | Agents therapeutiques chimeriques | |
CA2579523A1 (fr) | Molecules de liaison destinees au traitement et a la detection du cancer | |
BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
WO2006028429A3 (fr) | Peptide pour cibler l'antigene prostatique membranaire specifique | |
NZ504938A (en) | Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen | |
WO2005123760A3 (fr) | Traitement du cancer | |
WO2006083562A3 (fr) | Procede et conjugues a composants multiples permettant de traiter le cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |